News

July 25, 2019

Obsidian Therapeutics Announces Strengthening of Executive Leadership Team

Obsidian Therapeutics Announces Strengthening of Executive Leadership Team Expanded Leadership Supports Company Evolution into Development-Stage Biotechnology Company using cytoDRiVE™ Technology to Regulate Cell and Gene Therapies […]
April 18, 2019

Obsidian Therapeutics Announces Leadership Transition

Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer Experienced CEO brings expertise in product development, cell and gene therapies, […]
January 18, 2019

Obsidian Therapeutics Announces Strategic Collaboration with Celgene

Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New […]
December 6, 2017

Obsidian Therapeutics Announces $49.5 Million Series A Financing

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products Financing led by GV to focus on lead programs for […]